Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that minoxidil may improve hypotrichosis in patients with ARWH due to LIPH variants, but a possible genetic factor could affect its efficacy within families.

This case report details a 54-year-old woman with metastatic non-small-cell lung cancer who experienced severe hair loss and exanthematous drug eruption, potentially linked to erlotinib hypersensitivity.

This case report describes a drug-related skin eruption following AstraZeneca-Oxford vaccination, which resolved after treatment with oral prednisolone.

This case study highlights that even short-term use of hydroxychloroquine for COVID-19 can potentially lead to acute generalized exanthematous pustulosis as an adverse effect.

A man developed a skin reaction from metronidazole, which improved after stopping the drug and starting steroids.

This report describes a case of acute localised exanthematous pustulosis in a 19-year-old boy after using amoxicillin-clavulanic acid, with new dermoscopic features identified.

Eating shiitake mushrooms caused a man to develop a rash similar to a skin condition known as AGEP.

Plaquenil can cause a severe skin reaction called AGEP, requiring prompt diagnosis and treatment.

This paper presents the first reported case of Acute Localized Exanthematous Pustulosis linked to topical minoxidil use, suggesting a contact-induced hypersensitivity reaction as a potential mechanism.

This case report describes a 45-year-old male with atrial fibrillation who developed acute generalized exanthematous pustulosis after starting metformin for prediabetes, highlighting a rare dermatologic reaction.

A 16-year-old girl's skin rash was likely caused by an infection and improved with topical steroids.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This study observed that among 206 children in India, skin infections and infestations were the most common skin conditions, highlighting a significant burden in developing countries and underscoring the importance of awareness and treatment in pediatric dermatological care.

COVID-19 can cause different skin issues, including rashes and hair loss.

This study found that the prevalence of dermatological manifestations in COVID-19 patients was 1.7% in Sri Lanka, with various types of skin lesions reported.

This article discusses the impact of COVID-19 on skin health, highlighting various cutaneous manifestations and the need for dermatologists to adapt their practices during the pandemic, but it reports no new results.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

This study found that the leading reason for dermatology consultations in a pediatric tertiary care hospital was unspecified rash, accounting for 16.1% of cases.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This review discusses dermatologic manifestations of COVID-19, highlighting the possibility that skin signs might be the initial indicators of infection, though it reports no new clinical results.

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

This review discusses various skin infections and conditions that commonly occur in patients with HIV, but it does not report new research findings.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This review discusses the distinctive non-infective skin presentations of HIV infection from a dermatological perspective and reports no new clinical findings.

This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.